Roche granted approval for ocrelizumab (multiple sclerosis) in Europe

Roche has announced that the European Commission has granted a marketing authorization to ocrelizumab, for the treatment of patients with relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. The European Commission has considered the positive results from the Phase-III Opera 1 and Opera 2 clinical trials, which have demonstrated ocrelizumab’s efficacy in 80% of the cases. Multiple sclerosis approximately affects 700,000 people in Europe, approximately 96,000 of whom are diagnosed its primary progressive form.
(Source: Roche)